POSACONAZOLE TIH posaconazole 40 mg/mL oral suspension bottle

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

posaconazole, Quantity: 40 mg/mL

Pieejams no:

Arrotex Pharmaceuticals Pty Ltd

Zāļu forma:

Oral Liquid, suspension

Kompozīcija:

Excipient Ingredients: PEG-40 hydrogenated castor oil; sodium benzoate; citric acid monohydrate; glycerol; purified water; liquid glucose; xanthan gum; sodium citrate dihydrate; titanium dioxide; PEG-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; Flavour

Ievadīšanas:

Oral

Vienības iepakojumā:

1 x 105 mL bottle

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the: ? Treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.

Produktu pārskats:

Visual Identification: Posaconazole 40 mg/mL Suspension is a white to off-white free flowing suspension.; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorizācija statuss:

Registered

Autorizācija datums:

2023-01-18